In 2003, results were presented from two pivotal phase-III clinical trials testing the efficacy of daily intravenous<unk>  for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) caused by Gram-positive bacteria. The primary endpoints of both studies were met, with<unk>  achieving efficacy with fewer days of therapy than the comparator agents vancomycin followed by cephalexin.<unk>  showed a statistically significant improved safety profile with a 19% relative reduction in the overall incidence of adverse events versus vancomycin/cephalexin in the second and larger pivotal trial. Osteomyelitis remains a formidable foe in an era of increasing incidence of Methicillin-resistant Staphylococcus aureus (MRSA) with limited guidance for treatment optimization. The success observed in many patients suggests multi-dose<unk>  may prove advantageous for chronic osteomyelitis but further research is needed to define the optimal dose and frequency of<unk>  for the treatment of chronic osteomyelitis.
Oritavancin
Rifampicin
Amikacin
Telithromycin
Dalbavancin
Milbemycin
Moxifloxacin
Milbemycin oxime